drugset / Trial / NCT05036876

Degludec Glargine U300 Hospital Study

NCT05036876

Completed 220 enrolled Medanta, The Medicity, India
RandomizedParallel-groupOpen-labelTreatment

Summary

Limited data exist about the use of insulin degludec and insulin glargine U300 in the hospitalized patients. A previous study compared the safety and efficacy of insulin degludec versus insulin glargine U100 for the management of hospitalized patients with type 2 diabetes. However, there is no data comparing the efficacy and safety of insulin degludec versus insulin glargine U300 for the management of hospitalized patients with type 2 diabetes. Accordingly, the proposed study will provide a clinically useful information on the efficacy (blood glucose control) and safety (hypoglycemia) of insulin degludec versus insulin glargine U300 for the management of hospitalized patients with type 2 diabetes.

Timeline

Start
2021-10-10
Primary completion
2022-03-01
Completion
2022-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Degludec Protein / enzyme biologic 30 iu
Subject Degludec Protein / enzyme biologic 40 iu
Comparator insulin glargine Protein / enzyme biologic 30 iu
Comparator insulin glargine Protein / enzyme biologic 40 iu